# EDGAR Filing Document

**Accession Number:** 0001099800
**File Stem:** 0001099800-25-000046
**Filing Date:** 2025-8
**Character Count:** 10971
**Document Hash:** 5371c18b093eb034ee9f0aa4733b5937
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001099800-25-000046.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0001099800-25-000046

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250806

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250806

**DATE AS OF CHANGE**: 20250806

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Edwards Lifesciences Corp
- **CENTRAL INDEX KEY:** 0001099800
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364316614
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15525
- **FILM NUMBER:** 251188757

**BUSINESS ADDRESS:**
- **STREET 1:** ONE EDWARDS WAY
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614
- **BUSINESS PHONE:** 9492502500

**MAIL ADDRESS:**
- **STREET 1:** ONE EDWARDS WAY
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EDWARDS LIFESCIENCES CORP.
- **DATE OF NAME CHANGE:** 20090225

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EDWARDS LIFESCIENCES CORP
- **DATE OF NAME CHANGE:** 20000203

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CVG CONTROLLED INC
- **DATE OF NAME CHANGE:** 19991126

?xml version='1.0' encoding='ASCII'? ew-20250806

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) August 6, 2025

**EDWARDS LIFESCIENCES CORPORATION** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-15525** | **36-4316614** |
| (State or other jurisdiction<br>of incorporation) | (Commission<br>file number) | (IRS Employer<br>Identification No.) |

---

**One Edwards Way** 

**Irvine, California 92614** 

(Address of principal executive offices and zip code)

**(949) 250-2500** 

(Registrant's telephone number, including area code)

---

| |
|:---|
| **N/A** |
| (Former name or former address, if changed since last report**)** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| Common Stock, par value $1.00 per share | EW | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01. Regulation FD Disclosure.**

On August 6, 2025, Edwards Lifesciences Corporation (the "Company") issued a press release announcing that the U.S. Federal Trade Commission has moved to block the Company's proposed acquisition of JenaValve Technology, Inc.

A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.** 

---

| | |
|:---|:---|
| **(d)** | **Exhibits** |
| 99.1 | Press Release of Edwards Lifesciences Corporation, dated as of August 6, 2025. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **EDWARDS LIFESCIENCES CORPORATION** | **EDWARDS LIFESCIENCES CORPORATION** |
| | By: | /s/ Mark D. Peterson |
| | | Mark D. Peterson |
| Date: August 6, 2025 |  | Corporate Vice President, General Counsel |

---

------

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | [Press Release of Edwards Lifesciences Corporation, dated as of](axjenavalvexexhpressreleas.htm)[August](axjenavalvexexhpressreleas.htm)[6](axjenavalvexexhpressreleas.htm)[, 2025](axjenavalvexexhpressreleas.htm)[.](axjenavalvexexhpressreleas.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

## Exhibit 99.1

**EXHIBIT 99.1**

---

| | |
|:---|:---|
| ![image_0.jpg](image_0.jpg) | **Edwards Lifesciences Corporation**<br>One Edwards Way Irvine, CA USA 92614 <br>Phone: 949.250.2500 Fax: 949.250.2525<br>www.edwards.com |

---

Media Contact: Amy Meshulam, 949-250-4009

Investor Contact: Mark Wilterding, 949-250-6826

**EDWARDS LIFESCIENCES COMMENTS ON FTC'S ACTION TO BLOCK PROPOSED ACQUISITION OF JENAVALVE**

**IRVINE, CA – August 6, 2025** – Edwards Lifesciences (NYSE: EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition of JenaValve Technology.

Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believes the acquisition of JenaValve will accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR.

AR is a deadly and progressive disease that affects a significant and growing number of patients, many of whom currently have limited treatment options.

Edwards intends to continue to pursue regulatory approval of the acquisition and estimates a final determination by the end of Q1 2026.

In light of FTC's action, Edwards is revising its full-year 2025 financial guidance. There is no impact to revenue guidance. The company is increasing its adjusted<sup>1</sup> Earnings Per Share (EPS) guidance for the full year to the high-end of $2.45-$2.55, up from the high-end of $2.40-$2.50. There will be minimal impact to the company's Q3 adjusted EPS guidance.

[1] Adjusted earnings per share is a non-GAAP item computed on a diluted basis and in this release also excludes certain litigation expenses, amortization of intangible assets, loss on impairment and separation costs. See "Non-GAAP Financial Information" in this release. Diluted earnings per share are from continuing operations.

------

**About Edwards Lifesciences**&nbsp;&nbsp;&nbsp;&nbsp;

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as "may," "might," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "intend," "optimistic," "aspire," "confident" and other forms of these words and include, but are not limited to, statements regarding the continued pursuit of regulatory approval, a final determination of the transaction by the end of the first quarter of 2026, impact on patient lives and the company's revised financial guidance and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.

**Non-GAAP Financial Information**

Projections for diluted earnings per share from continuing operations are provided on a non-GAAP basis as adjusted to exclude certain litigation expenses, amortization of intangible assets, loss on impairment, and separation costs. The company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown effect, timing, and potential significance of special charges or gains, and management's inability to forecast charges associated with future transactions and initiatives.

Edwards, Edwards Lifesciences, and the stylized E logo, are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

\# \# \#

<br>